Preprint Article Version 1 NOT YET PEER-REVIEWED

Efficacy and Safety of Eribulin in Taxane-Refractory Patients in the “Real World”

  1. Istituto Tumori Giovanni Paolo II IRCCS, Bari 70124, Italy
  2. Ospedale A. Perrino, Brindisi 72100, Italy
  3. Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan 19-20156, Italy
  4. IRCCS AOU San Martino-IST, Genova 10-16132, Italy
  5. Azienda Ospedaliera-Universitaria di Udine, Udine 33100, Italy
  6. A.S.S.T. Bergamo Ovest, Ospedale, Treviglio 24047, Italy
Version 1 : Received: 25 September 2016 / Approved: 26 September 2016 / Online: 26 September 2016 (11:39:32 CEST)

How to cite: Lorusso, V.; Cinieri, S.; Latorre, A.; Porcu, L.; Del Mastro, L.; Puglisi, F.; Barni, S. Efficacy and Safety of Eribulin in Taxane-Refractory Patients in the “Real World”. Preprints 2016, 2016090093 (doi: 10.20944/preprints201609.0093.v1). Lorusso, V.; Cinieri, S.; Latorre, A.; Porcu, L.; Del Mastro, L.; Puglisi, F.; Barni, S. Efficacy and Safety of Eribulin in Taxane-Refractory Patients in the “Real World”. Preprints 2016, 2016090093 (doi: 10.20944/preprints201609.0093.v1).

Abstract

Taxanes have been shown to be the most effective treatment for recurrent or metastatic breast cancer. However, for patients pretreated with taxanes, more active and possibly less toxic drugs are needed. In this retrospective study, we investigated on the effectiveness and safety of eribulin mesylate in 91 taxane-refractory subjects, extracted from the ESEMPIO database, which included 497 metastatic breast cancer patients treated with eribulin allover the Italy. This analysis included only those patients who have shown disease progression while receiving taxane therapy (primary refractory), or those who achieved a response followed by progression while still on therapy (taxane failure). Overall, 41/91 patients (45.2%) showed a clinical benefit; 1 complete response (2.2%) and 16 partial responses (17.6%) were observed. The median progression free survival was 3.1 months (95% CI: 2.8–3.5) and the median overall survival was 11.6 months (95% CI: 8.7–16.7). With regard to toxicity, 53 patients (58%) experienced asthenia/fatigue, 23 (25%) showed peripheral neurotoxicity, 18 (20%) alopecia, 12 (13%) mild constipation and 27 (30%) neutropenia. The toxicity related to the treatment led to eribulin dose reduction in 19 (21%) and discontinuation in 9 (10%) patients, respectively. In conclusion, this study suggests that eribulin is effective and well tolerated also in taxane-refractory patient.

Subject Areas

metastatic breast cancer; taxanes; eribulin; observational study

Readers' Comments and Ratings (0)

Discuss and rate this article
Views 106
Downloads 145
Comments 0
Metrics 0
Discuss and rate this article

×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.